Illumina price target raised to $290 from $270 at Canaccord. Canaccord analyst Mark Massaro raised his price target on Illumina to $290 from $270 and said it remains a “must-own” large cap stock. The company remains a top pick given its dominant leadership in the next-gen sequencing market. He sees room for raised guidance in 2018 given rising demand for NGS consumables and array consumables/services. Massaro reiterated his Buy rating on Illumina shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.